Oryzon Genomics S.A.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Oryzon Genomics S.A. generated cash of -$634,754, which is more than the previous year. Cash used in financing activities reached the amount of $6,647,347 last year. Net change in cash is therefore -$9,294,073.
Cash Flow
| 2014 | 12.12M | -7.45M | -3.24M |
|---|---|---|---|
| 2015 | 568.16K | 121.06K | 16.50M |
| 2016 | -5.00M | -7.10M | 14.66M |
| 2017 | -5.64M | 771.37K | 20.38M |
| 2018 | -666.09K | -6.97M | 7.01M |
| 2019 | -4.41M | -10.74M | 15.99M |
| 2020 | -5.88M | -11.09M | 22.45M |
| 2021 | -4.12M | -13.34M | 4.69M |
| 2022 | -1.97M | -15.28M | 9.32M |
| 2023 | -634.75K | -16.01M | 6.64M |
0RDB.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 22.82M | 32.69M | 48.38M | 39.38M | 39.31M | 34.95M | 23.18M | 19.46M | 4.39M | 2.03M |
Operating activities | ||||||||||
Net income | -3.70M | -4.53M | -5.33M | -4.15M | -4.13M | -1.17M | -6.23M | -5.44M | -1.07M | 6.65M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 168.78K | 156.96K | 151.53K | 162.00K | 155.08K | 139.23K | 195.08K | 182.42K | 234.34K | 228.97K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 371.33K | 307.40K | -125.04K | 192.40K | -361.32K | -114.67K | 362.01K | 40.28K | -320.90K | -41.15K |
Inventories | 4.16K | 100.65K | 242.47K | -34.23K | -173.08K | -127.22K | 1.26K | -4.39K | 5.43K | -6.73K |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -634.75K | -1.97M | -4.12M | -5.88M | -4.41M | -666.09K | -5.64M | -5.00M | 568.16K | 12.12M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -80.94K | -199.61K | -186.51K | -129.36K | -169.63K | -125.99K | -28.48K | -95.19K | -47.29K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
Cash generated by investing activities | -16.01M | -15.28M | -13.34M | -11.09M | -10.74M | -6.97M | 771.37K | -7.10M | 121.06K | -7.45M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -1.98M | -1.07M | 0 | 0 | 0 | 0 | -3.70M | -1.89M | 0 | -1.49M |
Repayments of term debt | -5.58M | 736.49K | -4.69M | -244.92K | -4.61M | 0 | 119.73K | 0 | -103.14K | 0 |
Cash used in financing activities | 6.64M | 9.32M | 4.69M | 22.45M | 15.99M | 7.01M | 20.38M | 14.66M | 16.50M | -3.24M |
Net Change In Cash | -9.29M | -9.86M | -15.68M | 8.99M | 67.39K | -630.71K | 18.74M | 2.56M | 16.74M | 1.59M |
Cash at end of period | 13.53M | 22.82M | 32.69M | 48.38M | 39.38M | 34.31M | 41.93M | 22.02M | 21.14M | 3.63M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |